 |
McKenzie, Patti, Heather, Jeannine, Yvonne & Anne's Training Site |
|
|||||
My Educational Video on MS and MS Trials| Visitors..Plus 221,000 on MySpace |
||||||||||||||||||||||||||||||||||||||||
| Click here to go to our MySpace Page HERE'S A FEW OF OUR 3,200 MySpace FRIENDS |
||||||||||||||||||||||||||||||||||||||||
 |
||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
 Click to view 1280 MS Walk photos! | ||||||||||||||||||||||||||||||||||||||||
| "Join a trial at Barrow & receive all medication & study based procedures at no charge!" | ||||||||||||||||||||||||||||||||||||||||
Stan Swartz, CEO, The MD Health Channel "WE PRODUCED THE FOLLOWING 9 VIDEOS FOR YOU!" Simply click the "video" buttons below: . |
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| Previious Posts | ||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||
| MS NEWS ARCHIVES: by week | ||||||||||||||||||||||||||||||||||||||||
| January 2007 | ||||||||||||||||||||||||||||||||||||||||
| November 2007 | ||||||||||||||||||||||||||||||||||||||||
| April 2008 | ||||||||||||||||||||||||||||||||||||||||
| July 2008 | ||||||||||||||||||||||||||||||||||||||||
| December 2008 | ||||||||||||||||||||||||||||||||||||||||
| January 2009 | ||||||||||||||||||||||||||||||||||||||||
| February 2009 | ||||||||||||||||||||||||||||||||||||||||
| March 2009 | ||||||||||||||||||||||||||||||||||||||||
| March 2010 | ||||||||||||||||||||||||||||||||||||||||
| April 2010 | ||||||||||||||||||||||||||||||||||||||||
| May 2010 | ||||||||||||||||||||||||||||||||||||||||
| August 2010 | ||||||||||||||||||||||||||||||||||||||||
| May 2013 | ||||||||||||||||||||||||||||||||||||||||
| June 2013 | ||||||||||||||||||||||||||||||||||||||||
| July 2013 | ||||||||||||||||||||||||||||||||||||||||
| January 2014 | ||||||||||||||||||||||||||||||||||||||||
| February 2014 | ||||||||||||||||||||||||||||||||||||||||
| March 2014 | ||||||||||||||||||||||||||||||||||||||||
| April 2014 | ||||||||||||||||||||||||||||||||||||||||
7/31/13
4 New stories
The Multiple Sclerosis Intimacy and Sexuality Questionnaire
Cognitive reserve in Multiple Sclerosis
Relapse of multiple sclerosis in a patient under fingolimod therapy
Anatomical brain connectivity can assess cognitive dysfunction
Cognitive reserve in Multiple Sclerosis
Relapse of multiple sclerosis in a patient under fingolimod therapy
Anatomical brain connectivity can assess cognitive dysfunction
7/23/13
New Breaking Stories
Biogen Idec's long-acting beta interferon moves ahead
THC In Cannabis Does Not Slow....
New drugs ease symptoms ....
THC In Cannabis Does Not Slow....
New drugs ease symptoms ....
Boston Scientific evaluates neurostimulation
7/22/13
Practice adding links to this post below. try to keep the headlines as short as possible! go this site to learn how they shorten headlines: www.DrudgeReport.com
A comparative
study of magnetic resonance venography techniques for the evaluation of
the internal jugular veins in multiple sclerosis patients.
Acute Disseminated Encephalomyelitis (MS) in Children and Adolescents: A Single Center Experience.
Determinants of sexual dysfunction in women with multiple sclerosis.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy
No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis
Biogen Idec and the University of Edinburgh have agreed to a three-year collaboration in which they plan to study multiple sclerosis (MS) and motor neuron disease, then identify drug compounds that could potentially be used as treatments.
Scientists in bid to pinpoint undiscovered MS treatments
Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
Drugs prescribed to people with motor neurone disease, asthma and heartdisease could be used to help improve the lives of patients with advancedmultiple sclerosis
Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis
Fluctuations in appraisal over time in the context of stable versus non-stable health.
Genetic factors and multiple sclerosis in the Moroccan population: A role for HLA class II.
Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β
Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Device restores mobility to 40-year-old teacher-After five years of struggling to walk because of theeffects of multiple sclerosis, Lisa Curtis stepped out Friday, July 19,with a spring in her step. The spring – a real metal spring – was part of a new device developed to help....
Natural myelin regeneration is the next multiple sclerosis therapy. CLICK FOR SLIDESHOW & VIDEO
NEW PROGRESSIVE MS DRUG: FediciNova has announced the initiation of a cooperative Phase IIb trial of MN-166 in patients with progressive multiple sclerosis (progressive MS).
NEW DRUG FOR PROGRESSIVE MS: Cleveland Clinic to lead $11.3 million MS drug study designed to evaluate the safety and effectiveness of ibudilast, an oral drug, in the treatment of progressive multiple sclerosis patients
The world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries is applying to Expand Sativex® Approval for France.
Should Multiple Sclerosis Drugs Cost $62,000 a Year? The first in a two-part series examines the business of Big Pharma and the role of patents and competition in the drug pricing process.
Patient enrollment this fall for progressive multiple sclerosis MN-166 trial. Dr. Robert Fox and colleagues at Cleveland's Mellen Center for Multiple Sclerosis are working with co-investigators at 20 additional academic centers on a clinical trial for those suffering from progressive-types of multiple sclerosis (MS).
Emily Gauthier: Inspired to Ride 120 Miles for MS.The 46-year-old has relapsing remitting multiple sclerosis, but that hasn't affected her desire to tackle big physical challenges. Last weekend,Gauthier biked 120 miles, from Fenton, Mich., to Michigan State Universityin East Lansing and back to ...
Device restores mobility to 40-year-old teacher-After five years of struggling to walk because of theeffects of multiple sclerosis, Lisa Curtis stepped out Friday, July 19,with a spring in her step. The spring – a real metal spring – was part of a new device developed to help....
Vickie George, a passionate outdoor adventurist who in 1995 was diagnosedwith progressive multiple sclerosis, has inspired UD engineering students
Emmy award winner, Andrew Morreale creates documentary to bring a deeper understanding to thedifficulty of living with Multiple Sclerosis.
Acute Disseminated Encephalomyelitis (MS) in Children and Adolescents: A Single Center Experience.
Determinants of sexual dysfunction in women with multiple sclerosis.
Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use.
Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis.
Clinically isolated syndromes with no further disease activity suggestive of multiple sclerosis at the age of population life expectancy
No Evidence for Impairment of Venous Hemodynamics in Children or Young Adults with Pediatric-Onset Multiple Sclerosis
Biogen Idec and the University of Edinburgh have agreed to a three-year collaboration in which they plan to study multiple sclerosis (MS) and motor neuron disease, then identify drug compounds that could potentially be used as treatments.
Scientists in bid to pinpoint undiscovered MS treatments
Betaferon efficiency indicators in the treatment of relapsing remitting form of multiple sclerosis.
Drugs prescribed to people with motor neurone disease, asthma and heartdisease could be used to help improve the lives of patients with advancedmultiple sclerosis
Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis
Fluctuations in appraisal over time in the context of stable versus non-stable health.
Genetic factors and multiple sclerosis in the Moroccan population: A role for HLA class II.
Use of a Standardized MxA Protein Measurement-Based Assay for Validation of Assays for the Assessment of Neutralizing Antibodies Against Interferon-β
Psychological and physical predictors of illness intrusiveness in patients with multiple sclerosis.
Device restores mobility to 40-year-old teacher-After five years of struggling to walk because of theeffects of multiple sclerosis, Lisa Curtis stepped out Friday, July 19,with a spring in her step. The spring – a real metal spring – was part of a new device developed to help....
Natural myelin regeneration is the next multiple sclerosis therapy. CLICK FOR SLIDESHOW & VIDEO
NEW PROGRESSIVE MS DRUG: FediciNova has announced the initiation of a cooperative Phase IIb trial of MN-166 in patients with progressive multiple sclerosis (progressive MS).
NEW DRUG FOR PROGRESSIVE MS: Cleveland Clinic to lead $11.3 million MS drug study designed to evaluate the safety and effectiveness of ibudilast, an oral drug, in the treatment of progressive multiple sclerosis patients
The world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 21 countries is applying to Expand Sativex® Approval for France.
Should Multiple Sclerosis Drugs Cost $62,000 a Year? The first in a two-part series examines the business of Big Pharma and the role of patents and competition in the drug pricing process.
Patient enrollment this fall for progressive multiple sclerosis MN-166 trial. Dr. Robert Fox and colleagues at Cleveland's Mellen Center for Multiple Sclerosis are working with co-investigators at 20 additional academic centers on a clinical trial for those suffering from progressive-types of multiple sclerosis (MS).
Emily Gauthier: Inspired to Ride 120 Miles for MS.The 46-year-old has relapsing remitting multiple sclerosis, but that hasn't affected her desire to tackle big physical challenges. Last weekend,Gauthier biked 120 miles, from Fenton, Mich., to Michigan State Universityin East Lansing and back to ...
Device restores mobility to 40-year-old teacher-After five years of struggling to walk because of theeffects of multiple sclerosis, Lisa Curtis stepped out Friday, July 19,with a spring in her step. The spring – a real metal spring – was part of a new device developed to help....
Vickie George, a passionate outdoor adventurist who in 1995 was diagnosedwith progressive multiple sclerosis, has inspired UD engineering students
Emmy award winner, Andrew Morreale creates documentary to bring a deeper understanding to thedifficulty of living with Multiple Sclerosis.